Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Vorinostat × Other solid neoplasm × Clear all

Phase

Phase 1 8 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 14 Other hematologic neoplasm 9 Thoracic 7 Sarcoma 5 CNS 5 Dermatologic 4 Breast 4 Plasma cell 3 Myeloid 2 Gynecologic 2 Genitourinary 2 Gastrointestinal 2 Other solid neoplasm 1 Head & Neck 1 Classical hematology 1

Conditions

Mesothelioma, Malignant 1 Mesothelioma 1

Interventions

pembrolizumab 37 Injections 33 toripalimab 20 Bevacizumab 16 Nivolumab 15 Cisplatin 15 Pemetrexed 14 Paclitaxel 14 Cyclophosphamide 14 Carboplatin 14 fludarabine 9 Irinotecan 9 Ipilimumab 9 tislelizumab 8 Leucovorin 8 Gemcitabine 8 Fluorouracil 8 Docetaxel 8 atezolizumab 7 spartalizumab 6 Oxaliplatin 6 Albumin-Bound Paclitaxel 5 trifluridine tipiracil drug combination 4 sintilimab 4 palbociclib 4 lenvatinib 4 Radiosurgery 4 Interleukin-2 4 Fulvestrant 4 Capecitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01353482 2012-03-22

MESO-02

University College, London

Phase 1/2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡